Skip to main content

Table 1 Demographic and clinicopathological characteristics of AML patients

From: Interleukin-4 gene intron 3 VNTR polymorphism in adult acute myeloid leukemia

Variables AML patient (n = 60)
Age (years), Mean ± SD 43.1 ± 14.3
Sex, n (%)
 Male 42 (70)
 Female 18 (30)
Extramedullary involvement, n (%)
 Positive 34 (56.7)
 Negative 26 (43.3)
TLC (× 103/µL), Median (IQR) 19.5 (5.8–58)
Hemoglobin (g/dL), mean ± SD 7.5 ± 2.2
Platelets (× 103/µL), Median (IQR) 40.5 (15–79)
PB blasts (%), Median (IQR) 32 (5–63)
Initial BM blasts (%), Median (IQR) 69 (50–85)
FAB subtype, n (%)
 M0 3 (5.0)
 M1 12 (20)
 M2 32 (53.3)
 M4 11 (18.3)
 M5 0 (0.0)
 M6 0 (0.0)
 M7 2 (3.3)
Immunophenotyping, n (%)
 HLA-DR 53 (88.3)
 CD34 49 (81.7)
 MPOX 50 (83.3)
Cytogenetic risk groups, n (%)
 Favorable 7 (11.66)
 Intermediate 38 (63.33)
 Poor 5 (8.33)
 NA* 10 (16.66)
  1. MPOX myeloperoxidase, NA not applicable, *ten patients (16.66%) non-provided data Or failed cytogenetic analysis, Favorable cytogenetic markers: t(8;21), inv(16); Intermediate cytogenetic markers: normal karyotype, trisomy 8; Unfavorable cytogenetic markers t(11q23), t(9;11), monosomy7